Stifel Nicolaus Boosts GH Research (NASDAQ:GHRS) Price Target to $32.00

GH Research (NASDAQ:GHRS) had its target price hoisted by equities research analysts at Stifel Nicolaus from $18.00 to $32.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ price target suggests a potential upside of 215.89% from the stock’s previous close.

Several other analysts have also recently weighed in on the stock. Cantor Fitzgerald began coverage on shares of GH Research in a report on Thursday, February 13th. They issued an “overweight” rating and a $14.00 target price on the stock. Canaccord Genuity Group decreased their price objective on shares of GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of GH Research in a research note on Monday, January 27th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, GH Research has a consensus rating of “Buy” and a consensus target price of $30.60.

GH Research Trading Down 4.9 %

GH Research stock opened at $10.13 on Thursday. The firm has a market capitalization of $527.04 million, a P/E ratio of -12.82 and a beta of 0.93. GH Research has a twelve month low of $6.00 and a twelve month high of $20.50. The stock’s fifty day simple moving average is $10.51 and its 200-day simple moving average is $9.20.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.06. Sell-side analysts predict that GH Research will post -0.8 earnings per share for the current year.

Institutional Trading of GH Research

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. RA Capital Management L.P. grew its position in shares of GH Research by 1.3% in the 3rd quarter. RA Capital Management L.P. now owns 6,686,689 shares of the company’s stock valued at $44,734,000 after buying an additional 85,000 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of GH Research by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 72,513 shares of the company’s stock worth $508,000 after purchasing an additional 3,092 shares during the last quarter. Diadema Partners LP purchased a new position in shares of GH Research during the fourth quarter worth about $711,000. Lynx1 Capital Management LP increased its position in shares of GH Research by 15.8% during the fourth quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company’s stock worth $34,013,000 after purchasing an additional 663,100 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in shares of GH Research by 26.8% in the 4th quarter. Northern Trust Corp now owns 40,834 shares of the company’s stock valued at $286,000 after purchasing an additional 8,641 shares during the last quarter. Institutional investors and hedge funds own 56.90% of the company’s stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).